Figure 3From: Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model Viral RNA levels in vaccinated macaques (A72, A73, A74 and A78; group B: blue lines) and contemporaneous controls given ASO2 A adjuvant only (B238-241; group D: red lines) after challenge with 50MID 50 SHIV SF33 and followed for twenty weeks. Back to article page